Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

被引:396
|
作者
Schalm, SW
Heathcote, J
Cianciara, J
Farrell, G
Sherman, M
Willems, B
Dhillon, A
Moorat, A
Barber, J
Gray, DF
机构
[1] Erasmus Univ Hosp Rotterdam, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands
[2] Toronto Hosp, Div Gastroenterol, Toronto, ON M5T 2S8, Canada
[3] Med Acad Warsaw, Dept Hepatol & Infect Dis, Warsaw, Poland
[4] Univ Sydney, Storr Liver Unit, Westmead Hosp, Sydney, NSW, Australia
[5] Univ Hosp Montreal, Dept Gastroenterol & Hepatol, Montreal, PQ, Canada
[6] Royal Free Hosp, Dept Histopathol, London NW3 2QG, England
[7] Glaxo Wellcome Res & Dev Ltd, Greenford, Middx, England
关键词
chronic hepatitis B; hepatitis B virus; nucleoside analogue; lamivudine; alpha interferon; combination therapy; HBeAg seroconversion;
D O I
10.1136/gut.46.4.562
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background, aim, and methods-Alpha interferon is the generally approved therapy for HBe antigen positive patients with chronic hepatitis B, but its efficacy is limited. Lamivudine is a new oral nucleoside analogue which potently inhibits hepatitis B virus (HBV) DNA replication. To investigate the possibility of an additive effect of interferon-lamivudine combination therapy compared with interferon or lamivudine monotherapy, we conducted a randomised controlled trial in 230 predominantly Caucasian patients with hepatitis B e antigen (HBeAg) and HBV DNA positive chronic hepatitis IZ. Previously untreated patients were randomised to receive: combination therapy of lamivudine 100 mg daily with alpha interferon 10 million units three times weekly for 16 weeks after pretreatment with lamivudine for eight weeks (n=75); alpha interferon 10 million units three times weekly for 16 weeks (n=69); or lamivudine 100 mg daily for 52 weeks (n=82). The primary efficacy end point was the HBeAg seroconversion rate at week 52 (loss of HBeAg, development of antibodies to HBeAg and undetectable HBV DNA). Results-The HBeAg seroconversion rate at week 52 was 29% for the combination therapy, 19% for interferon monotherapy, and 18% for lamivudine monotherapy (p=0.12 and p=0.10, respectively, for comparison of the combination therapy with interferon or lamivudine monotherapy). The HBeAg seroconversion rates at week 52 for the combination therapy and lamivudine monotherapy were significantly different in the per protocol analysis (36% (20/56) v 19% (13/70), respectively; p=0.02). The effect of combining lamivudine and interferon appeared to be mast useful in patients with moderately elevated alanine aminotransferase levels at baseline. Adverse events with the combination therapy were similar to interferon monotherapy; patients receiving lamivudine monotherapy had significantly fewer adverse events. Conclusions-HBeAg seroconversion rates at one year were similar for lamivudine monotherapy (52 weeks) and standard alpha interferon therapy (16 weeks). The combination of lamivudine and interferon appeared to increase the HBeAg seroconversion rate, particularly in patients with moderately elevated baseline aminotransferase levels, The potential benefit of combining lamivudine and interferon should be investigated further in studies with different regimens of combination therapy.
引用
收藏
页码:562 / 568
页数:7
相关论文
共 50 条
  • [31] Comparative analysis of Peg-Interferon alpha-2b and lamivudine in the treatment of chronic hepatitis B patients
    Sidiropoulos, I
    Koliouskas, D
    Masmanidou, M
    Mandraveli, K
    Lazaraki, G
    Dokas, S
    Ziakas, A
    HEPATOLOGY, 2002, 36 (04) : 626A - 626A
  • [32] Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha
    Wicki, J
    Olivieri, J
    Pizzolato, G
    Sarasin, F
    Guillevin, L
    Dayer, JM
    Chizzolini, C
    RHEUMATOLOGY, 1999, 38 (02) : 183 - 185
  • [33] Prospective randomized study comparing combination of pegylated interferon and lamivudine versus lamivudine monotherapy for chronic hepatitis B infection
    Sung, JJ
    Chan, HL
    Chan, FK
    Wong, ML
    Hui, AY
    Leung, NW
    HEPATOLOGY, 2002, 36 (04) : 628A - 628A
  • [34] Combination Therapy With Lamivudine and Famciclovir for Chronic Hepatitis B Infection
    Shen, Hong
    Alsatie, Mazen
    Eckert, George
    Chalasani, Naga
    Lumeng, Lawrence
    Kwo, Paul Y.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (04) : 330 - 336
  • [35] Sequential treatment with lamivudine and interferon in patients with chronic hepatitis B non responder to interferon alone
    Thabut, D
    Serfaty, L
    Ardréani, T
    Fontaine, H
    Chazouillères, O
    Pol, S
    Poupon, R
    JOURNAL OF HEPATOLOGY, 2000, 32 : 103 - 103
  • [36] Evaluation of alpha interferon for the treatment of chronic hepatitis B infection in Christchurch
    Burt, MJ
    Ross, AG
    Schroeder, BA
    Chambers, ST
    Chapman, BA
    NEW ZEALAND MEDICAL JOURNAL, 1996, 109 (1021) : 162 - 164
  • [37] Efficacy of interferon α-2b and lamivudine combination treatment in comparison to interferon α-2b alone in chronic delta hepatitis:: A randomized trial
    Canbakan, B
    Senturk, H
    Tabak, F
    Akdogan, M
    Tahan, V
    Mert, A
    Sut, N
    Ozaras, R
    Midilli, K
    Ozbay, G
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (04) : 657 - 663
  • [38] Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B
    Danalioglu, A
    Karaca, C
    Akyuz, F
    Aksoy, N
    Demir, K
    Turkoglu, S
    Badur, S
    Besisik, F
    Cakaloglu, Y
    Okten, A
    Kaymakoglu, S
    HEPATOLOGY, 2002, 36 (04) : 635A - 635A
  • [39] Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B
    Danalioglu, A
    Kaymakoglu, S
    Cakaloglu, Y
    Demir, K
    Karaca, C
    Durakoglu, Z
    Bozaci, M
    Badur, S
    Cevikbas, U
    Okten, A
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (07) : 659 - 661
  • [40] Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine
    Hasan, F
    Al-Khaldi, J
    Asker, H
    Varghese, R
    Siddique, I
    Al-Shammali, M
    Al-Kalaoui, M
    Al-Nakib, B
    HEPATO-GASTROENTEROLOGY, 2003, 50 (54) : 2040 - 2042